Toggle menu

4AT Study

Start date:
August 2015
End date:
Predicted June 2017
Co-ordinated by:
EMERGE team on behalf of University of Edinburgh and NHS Lothian
Main trial site:
RIE

The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients.

Aim

To determine the diagnostic accuracy of the 4AT for delirium versus the reference standard of a DSM-IV diagnosis

Trial Design

Patients undergo a standard delirium assessment, and either the 4AT or the Confusion Assessment Method (CAM). Clinical outcomes and resource utilisation are recorded at 12 weeks after admission.

Eligibility criteria

Patients aged over 70 admitted to the Emergency Department.

Chief Investigator

Professor Alasdair MacLullich

Professor of Geriatric Medicine

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Jill Steven

Senior Research Nurse - 4AT study

Mia Paderanga

Senior Research Nurse

Megan McGrath

Senior Research Nurse

Emma Ward

Research Administrator

Related news

4AT team attends British Geriatric Society conference

4AT team attends British Geriatric Society conference

5 Nov 2015 | Allan MacRaild

Emerge sent two research nurses to the British Geriatric Society (BGS) conference. Jill Steven and Allan MacRaild are recruiting to a study entitled The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients. This study is a first collaboration between Emerge and Medicine of the Elderly with this study being led by Professor Alasdair MacLullich.

Read more
A study to assess a tool to diagnose Delirium

More EMERGE Trials

PRIEST

Pandemic Respiratory Infection Emergency System Triage

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy